[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-kidney-injury-aki\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-kidney-injury-aki":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,53,76,114,140,165,188,213,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100639725","coordinated-communication-education-and-care-transitions-after-acute-kidney-injury-connect-aki--a-pilot-randomized-controlled-trial-100639725",false,"NCT07626268","COordiNated CommuNication, Education, and Care Transitions After Acute Kidney Injury (CONNECT-AKI)- A Pilot Randomized Controlled Trial","CONNECT-AKI: COordiNated CommuNication, Education, and Care Transitions After Acute Kidney Injury - A Pilot Randomized Controlled Trial","CONNECT-AKI","Inclusion Criteria:\n\n* Age 18 years or older\n* Hospitalized with Stage 2 or Stage 3 acute kidney injury\n* Kidney function has not returned to baseline at the time of hospital discharge\n* Able to communicate in English\n* Able to provide informed consent\n* Willing and able to participate in study procedures independently or with assistance from a patient-designated care partner\n\nExclusion Criteria:\n\n* Acute kidney injury requiring ongoing dialysis at the time of hospital discharge\n* End-stage kidney disease\n* Kidney transplant recipient\n* Currently pregnant\n* Documented cognitive impairment that precludes informed consent\n* Receiving hospice or comfort-focused end-of-life care","ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether different ways of providing information and follow-up support after acute kidney injury, also called AKI, can improve care transitions for adults being discharged from the hospital. AKI is a sudden decrease in kidney function that can occur during a hospital stay.\n\nThe main questions this study aims to answer are:\n\n* Does an AKI discharge summary template improve communication about AKI after hospital discharge?\n* Does a chat-based educational messaging program improve patient understanding of AKI and support follow-up care after hospital discharge?\n* Researchers will compare usual care, an AKI discharge summary template, a chat-based educational messaging program, and the combination of the discharge summary template plus chat-based messaging.\n\nResearchers will compare four groups:\n\n* Usual care\n* An AKI discharge summary template\n* A chat-based educational messaging program\n* Both the AKI discharge summary template and the chat-based educational messaging program\n\nParticipants will complete questionnaires at the start of the study and about 4 weeks after hospital discharge. Participants will also receive a brief phone call about 3 months after discharge, and the research team will review their medical record for information about follow-up care, lab testing, emergency department visits, and hospital readmissions.",[27,28],"Acute Kidney Injury","Acute Kidney Injury (AKI)",[30,31,32,33,34,35,36,37,38,39,40],"Acute kidney injury","AKI","Hospital discharge","Care transitions","Post-discharge care","Patient education","Discharge communication","Discharge summary","Hospital readmission","Chat-based education","Digital health","NOT_YET_RECRUITING","2026-05-29",{"date":44,"type":45},"2026-06-04","ACTUAL",{"date":47,"type":21},"2026-06-01",{"date":49,"type":21},"2027-10-30",{"name":51,"class":52},"Northwell Health","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100639657","the-impact-of-blood-pressure-variability-during-the-induction-and-surgical-periods-on-postoperative-acute-kidney-injury-100639657","NCT07602465","The Impact of Blood Pressure Variability During the Induction and Surgical Periods on Postoperative Acute Kidney Injury","Inclusion Criteria:\n\n* Undergoing non-cardiac surgery；\n* Adult；\n\nExclusion Criteria:\n\n* Undergoing urological surgeries that partially directly affect kidney function (including relief of urinary tract obstruction, nephrectomy, or kidney transplantation);\n* Surgery duration less than 60 minutes;\n* Weight \\\u003C 30 kg or BMI \\> 35 kg\u002Fm2;\n* Patients who underwent reoperation within 7 days after surgery;\n* Surgeries not performed under general anesthesia;\n* ASA \\> IV;\n* No serum creatinine measurement available within 6 months before surgery (baseline value) or within 7 days after surgery;\n* Preexisting renal dysfunction or a diagnosis of chronic kidney disease before surgery (creatinine \\> 443 μmol\u002FL);\n* No invasive blood pressure monitoring during the anesthesia induction period, or missing more than 25% of intraoperative invasive blood pressure data collection.",{"count":60,"type":21},5000,"OBSERVATIONAL","The goal of this multicenter retrospective cohort study aimed to explore the effect of BPV during anesthesia induction and surgery on the occurrence of postoperative AKI in non-cardiac surgery patients.",[28],[30,65,66,67],"Blood pressure variability","Anesthesia induction period","Non-cardiac surgery","2026-05-21",{"date":70,"type":45},"2026-05-27",{"date":47,"type":21},{"date":73,"type":21},"2026-12-01",{"name":75,"class":52},"Zhongda Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":96,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100577740","phase-4-the-choice-of-vasopressor-to-prevent-postoperative-acute-kidney-injury-after-major-non-cardiac-surgery-100577740","NCT06802224","The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery","Norepinephrine vs Phenylephrine as the First-line Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-cardiac Surgery","VEGA-2","Inclusion Criteria:\n\n* Age 18 years or older\n* Surgery under general anesthesia with a surgery duration of 2 hours or more\n* Received intravenous vasopressors during surgery\n\nExclusion Criteria:\n\n* Cardiac surgery\n* Extra-corporeal membrane oxygenation\n* Organ transplantation\n* Obstetric procedures\n* Procedures on the kidney\n* Outpatient procedures\n* Already receiving NE or PE or inotropes before induction of anesthesia (at the time of anesthesia start)\n* American Society of Anesthesiologists physical status classification 5 or 6\n* Patient for whom a local protocol recommends a specific first line vasopressor\n* Most recent documented estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m\\^2 or preoperative renal replacement therapy within 60 days before surgery\n* Patients who do not have a preoperative creatinine value within 60 days before surgery\n* Alive patients who do not have a postoperative creatinine value",{"count":85,"type":21},18000,[87],"PHASE4","Low blood pressure, also known as hypotension, is very common during major surgery under general anesthesia. Prolonged or severe hypotension can lead to complications such as kidney injury after surgery that slow down patient recovery. Anesthesiologists commonly administer medications called vasopressors to treat low blood pressure during surgery. These medications help raise the blood pressure back up to a safe range. Two vasopressor medications are commonly used for this purpose: norepinephrine and phenylephrine. Each of these medications has slightly different effects on the heart and blood vessels (cardiovascular system). It remains unknown which of these standard medications is better for treating low blood pressure during surgery. The goal of this clinical trial is to determine which of these two medications is better at preventing injury to the kidneys after major noncardiac surgery as well as other complications such as heart problems. Major surgeries are defined as those lasting at least two hours under general anesthesia. This trial will randomize about ten centers in North America to use either norepinephrine or phenylephrine as the primary medication to treat low blood pressure in adults undergoing major noncardiac surgery. Each hospital will prioritize one of the drugs each month, and the assigned drug will rotate each month at each hospital. No further participant involvement will be required as de-identified data are collected as part of standard medical care.",[90,91,92,93,28,94,95],"Anesthesia","Surgery With General Anesthesia","Noncardiac Surgery","Hypotension During Surgery","Myocardial Injury After Noncardiac Surgery (MINS)","Vasopressor",[97,98,99,100,101,102],"Norepinephrine","Phenylephrine","Major adverse kidney events","Pragmatic","Cluster randomized","Crossover","RECRUITING","2026-05-20",{"date":106,"type":45},"2026-05-26",{"date":108,"type":45},"2025-04-01",{"date":110,"type":21},"2028-07",{"name":112,"class":52},"University of California, San Francisco",10,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100469954","phase-3-safety-evaluation-of-prismocitrate-18-in-patients-receiving-crrt-100469954","NCT05399537","Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT","A Safety Evaluation of Prismocitrate 18 in Patients Receiving Continuous Renal Replacement Therapy (CRRT)","Inclusion Criteria:\n\n* Patients must be ≥18 years of age\n* Patients who are candidates for CRRT\n* Patients expected to survive for at least 24 hours\n* Patients with a contraindication to heparin or an increased risk of hemorrhage\n* Patient and\u002For legally-authorized representative has signed a written informed consent form (ICF) per 21 CFR Part 50.55(e)\n\nExclusion Criteria:\n\n* Patients with a known allergy to citrate or who have ever experienced an adverse reaction associated with citrate products, including patients with a prior history of citrate toxicity\n* Patients with acute liver failure, defined by the occurrence of encephalopathy and hepatic synthetic dysfunction within 26 weeks of the first symptoms of liver disease and without evidence of chronic liver disease\n* Patients with acute-on-chronic liver failure characterized by acute decompensation of cirrhosis and a Child-Pugh Liver Failure Score \\>10\n* Patients with refractory shock and associated lactic acidosis (lactate \\>4 mmol\u002FL)\n* Patients with a systemic ionized calcium concentration outside the normal physiologic range (1.0 - 1.3 mmol\u002FL), or outside of the laboratory reference range (Note: It is acceptable to provide calcium supplementation or treatment for hypercalcemia to achieve a normal physiologic range prior to therapy initiation)\n* Female patients of childbearing potential who are pregnant or breastfeeding. (Note: All female patients, who have not undergone a hysterectomy, bilateral oophorectomy with or without hysterectomy, or has medically documented ovarian failure before study Screening must have a negative serum beta human chorionic gonadotropic \\[B-hCG\\] pregnancy test at Screening)\n* Patients who are currently participating in another interventional clinical study",{"count":122,"type":21},40,[124],"PHASE3","Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate anticoagulation (RCA) software to facilitate citrate and calcium compensation prescription.\n\nThe objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription.\n\nThe study period of the patient's CRRT will be up to 10 days.",[127,128,28],"Regional Citrate Anticoagulation (RCA)","Continuous Renal Replacement Therapy (CRRT)","2026-04-10",{"date":131,"type":45},"2026-04-13",{"date":133,"type":45},"2024-07-12",{"date":135,"type":21},"2026-12",{"name":137,"class":138},"Vantive Health LLC","INDUSTRY",14,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":61,"phases":4,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100618980","hamburg-acute-renal-injury-study-haris-100618980","NCT07338669","Hamburg Acute Renal Injury Study (HARIS)","Hamburg Acute Renal Injury Study","HARIS","Inclusion Criteria:\n\n* Hospitalized individuals with acute kidney injury (AKI), defined by the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria or hospitalized individuals with acute illness who have not developed AKI (control group)\n* Age ≥ 18 years at time of enrollment\n* Personally signed informed consent\n\nExclusion Criteria:\n\n* None",{"count":149,"type":21},1000,"1 Year","The Hamburg Acute Renal Injury Study (HARIS) is a prospective observational cohort study aimed at investigating the mechanisms, risk factors, and clinical determinants of acute kidney injury (AKI) trajectories and consequences.",[27,28],[27,31,154],"Prospective observational cohort study","2026-01-03",{"date":157,"type":45},"2026-01-14",{"date":159,"type":45},"2025-09-16",{"date":161,"type":21},"2030-09",{"name":163,"class":52},"Universitätsklinikum Hamburg-Eppendorf",1,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100610239","phase-2-trimethoprim-sulfamethoxazole-tmpsmx-prophylaxis-after-acute-kidney-injury-to-prevent-post-discharge-infections-100610239","NCT07224997","Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections","Inclusion Criteria\n\n* Age ≥18 years.\n* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.\n* Planned discharge to community\u002Frehabilitation with capacity for follow-up.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy to sulfonamides or TMP\u002FSMX.\n* Pregnancy or breastfeeding.\n* Severe hepatic disease (e.g., Child-Pugh C).\n* Severe cytopenia (e.g., ANC \\\u003C1.0×10⁹\u002FL or platelets \\\u003C50×10⁹\u002FL).\n* Baseline hyperkalemia (\\>5.5 mmol\u002FL) not correctable prior to randomization.\n* Concomitant medications with high-risk interactions not amenable to dose\u002Fmonitoring (per protocol).\n* Current systemic antimicrobial therapy planned for \\>14 days after discharge (prophylaxis not indicated).\n* Inability to adhere to study procedures or follow-up.",{"count":172,"type":21},120,[174],"PHASE2","Official Title\n\nTrimethoprim-Sulfamethoxazole (TMP\u002FSMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections: A Randomized, Double-Blind, Placebo-Controlled Trial\n\nBrief Summary\n\nAcute kidney injury (AKI) is commonly followed by infections after hospital discharge. This randomized, double-blind, placebo-controlled trial will test whether prophylactic TMP\u002FSMX reduces post-discharge infections in adults recently hospitalized with AKI. Participants will be randomized 1:1 to TMP\u002FSMX or matching placebo and followed for 6 months. The primary outcome is the proportion of participants who develop any infection within 90 days after discharge. Secondary outcomes include time to first infection, infection-related hospitalization, mortality, safety\u002Fadverse events, and healthcare utilization through 180 days.\n\nDetailed Description\n\nAdults discharged after an index hospitalization complicated by AKI are at elevated infection risk. This trial evaluates whether short-term TMP\u002FSMX prophylaxis reduces 90-day infections. After consent and eligibility confirmation near discharge, participants are randomized (1:1) to receive TMP\u002FSMX or matching placebo with double-blind masking (participant and outcome assessor). Dosing is standardized per protocol. We will ascertain infections via structured follow-up, medical record review, and adjudication by blinded assessors. Safety monitoring will capture adverse events (e.g., rash, cytopenias, hyperkalemia). Analyses follow intention-to-treat.\n\nStudy Design\n\n* Study Type: Interventional (Clinical Trial)\n* Primary Purpose: Prevention\n* Allocation: Randomized (1:1)\n* Intervention Model: Parallel Assignment\n* Masking: Double-blind (Participant, Outcomes Assessor)\n* Estimated Enrollment: 60 patients per group\n* Study Start Date: December 2025\n* Primary Completion Date (Anticipated): January 2027 (last patient reaches 90-day outcome)\n* Study Completion Date (Anticipated): July 2028 (last patient completes 180-day follow-up)\n\nArms \\& Interventions\n\nExperimental: TMP\u002FSMX\n\n* Intervention: Drug: Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) 160\u002F800 mg tablets every 48 hours\n* Dosing: One tablet by mouth, Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) 160\u002F800 mg tablets every 48 hours, for 90 days post-discharge.\n* Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F\n\nPlacebo Comparator: Placebo\n\n* Intervention: Drug: Placebo (matching oral tablet)\n* Dosing: Matching schedule for 90 days post-discharge.\n\nConcomitant care: Allowed per treating clinician. Drug interactions and lab monitoring handled per protocol.\n\nOutcome Measures\n\nPrimary Outcome\n\n• Any infection within 90 days after discharge Time Frame: Day 0 (discharge) to Day 90 Measure: Proportion of participants with ≥1 infection, defined by clinical diagnosis requiring documentation (e.g., UTI, pneumonia, SSTI, bloodstream infection) and\u002For antimicrobial treatment initiation.\n\nSecondary Outcomes\n\n1. Time to first infection (days) within 90 days.\n2. Infection-related hospitalization within 90 and 180 days.\n3. All-cause mortality at 90 and 180 days.\n4. Emergency department visits or unplanned readmissions within 180 days.\n5. Antibiotic-related adverse events (rash, cytopenia, creatinine rise ≥0.3 mg\u002FdL, hyperkalemia ≥5.5 mmol\u002FL) through 180 days.\n6. C. difficile infection within 180 days.\n7. Recurrent AKI (KDIGO criteria) within 180 days.\n8. Medication adherence (pill counts and\u002For self-report) over 90 days.\n9. Major adverse kidney events over 90 days.\n\nEligibility Criteria\n\nInclusion Criteria\n\n* Age ≥18 years.\n* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.\n* Planned discharge to community\u002Frehabilitation with capacity for follow-up.\n* Ability to provide informed consent.\n\nExclusion Criteria\n\n* Known allergy to sulfonamides or TMP\u002FSMX.\n* Pregnancy or breastfeeding.\n* Severe hepatic disease (e.g., Child-Pugh C).\n* Severe cytopenia (e.g., ANC \\\u003C1.0×10⁹\u002FL or platelets \\\u003C50×10⁹\u002FL).\n* Baseline hyperkalemia (\\>5.5 mmol\u002FL) not correctable prior to randomization.\n* Concomitant medications with high-risk interactions not amenable to dose\u002Fmonitoring (per protocol).\n* Current systemic antimicrobial therapy planned for \\>14 days after discharge (prophylaxis not indicated).\n* Inability to adhere to study procedures or follow-up.\n\nContacts\u002FLocations\n\n* Lead Sponsor \u002F Responsible Party: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología\n* Principal Investigator: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología, 3313299609\n* Study Locations: Hospital Civil de Guadalajara, servicio de Nefrología, Hospital 278, colonia el Retiro. Guadalajara. Jalisco.\n\nEthics and Oversight\n\n* Conducted in accordance with the Declaration of Helsinki and ICH-GCP.\n* IRB\u002FEthics approval: Comité de etica en investigacion, Protocol CEI 214\u002F25, Approval : October 16, 2025.\n* Written informed consent obtained from all participants prior to any study procedures.\n* Data",[177,178,28],"Acute Kidney Injuries","Acute Kidney Disease","2025-11-02",{"date":181,"type":45},"2025-11-05",{"date":183,"type":21},"2025-12-01",{"date":185,"type":21},"2027-07-01",{"name":187,"class":52},"Hospital Civil de Guadalajara",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":195,"sex":17,"minAge":196,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":164},"100610064","nirs-monitoring-in-the-nicu-and-aki-100610064","NCT07222722","NIRS Monitoring in the NICU and AKI","Near Infrared Spectroscopy (NIRS) Monitoring as an Early Predictor of Acute Kidney Injury (AKI) in a Vulnerable Neonatal Intensive Care Unit (NICU) Population","Inclusion Criteria:\n\n* Any neonate less than 30 weeks in gestational age\n* Willingness and capacity of both adult parents\u002Fguardians to sign consent\n\nExclusion Criteria:\n\n* An infant with known congenital anomalies of the kidney (i.e., grade 4 or 5 vesicoureteral reflux (VUR), posterior urethral valves, moderate or severe hydronephrosis, autosomal recessive polycystic kidney disease (ARPKD), bilateral renal agenesis or dysplasia)\n* Age \\>30 weeks gestational age\n* Age \\\u003C24 weeks and \\\u003C500 grams (will be excluded due to sensitivity of skin in this vulnerable population).\n* Clinician's decision that NIRS is not suitable due to the patient's clinical condition",true,"24 Weeks","30 Weeks",{"count":199,"type":21},100,[24],"The primary objective of this study is to describe the pattern of renal tissue oxygen saturation (SrSO2) using near-infrared spectroscopy (NIRS) in premature infants \\\u003C30 weeks gestational age. The secondary objective of this study is to evaluate prenatal and postnatal risk factors for acute kidney injury (AKI) in premature infants \\\u003C30 weeks gestational age. The investigators will also compare various rates of complications including death, length-of-stay, and prolonged duration of mechanical ventilation, among others.",[28,203],"Postnatal AKI","2025-10-29",{"date":206,"type":45},"2025-10-30",{"date":208,"type":21},"2025-11",{"date":210,"type":21},"2026-04-01",{"name":212,"class":52},"NYU Langone Health",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":164},"100609686","precision-medicine-diagnostic-support-in-hospitalized-veterans-with-acute-kidney-injury-100609686","NCT07217808","Precision-Medicine Diagnostic Support in Hospitalized Veterans With Acute Kidney Injury","PRECISE-AKI","Inclusion Criteria:\n\n* Eligible providers will be those that have at least 4 weeks of inpatient ward team or consultation team activity during a 12-month period.\n* Case inclusion criteria will consist of hospitalizations that meet criteria for Kidney Disease Improving Global Outcomes Stage 2 injury or persistent Stage 1 injury seen by eligible providers.\n\nExclusion Criteria:\n\n* Ineligible providers will be those that have \\\u003C 4 weeks of inpatient ward team of consultative team activity during a 12 month period.\n* Hospitalizations with non-persistent (\\\u003C48 hours) stage 1 injury or less.",{"count":221,"type":21},60,[24],"Acute kidney injury (AKI) affects up to 20% of hospitalized Veterans and is strongly associated with morbidity and death. AKI is a diverse condition and timely and accurate diagnosis of the type of AKI is critical to begin appropriate therapies, especially those causes that require specific treatments beyond general supportive care. Yet, there are still significant gaps in the initial evaluation of AKI among hospitalized patients. Clinical decision support systems (CDSS) have shown promise to address these barriers, but most consist of simple alerting schemes and general care recommendations provided at a single point in time. The goal of this proposal is to develop and test the feasibility and usability of a rule-based and Artificial Intelligence-assisted precision CDSS tool (PRECISE-AKI) that can provide cognitive support to improve timely initial diagnostic evaluation of AKI.",[28],[27,226,227],"Decision Support Systems, Clinical","Artificial Intelligence","2025-10-15",{"date":230,"type":45},"2025-10-16",{"date":232,"type":21},"2028-01-01",{"date":234,"type":21},"2029-06-30",{"name":236,"class":237},"VA Office of Research and Development","FED",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":164},"100606966","phase-4-ast-120-kremezin-for-the-renal-protection-and-attenuation-of-decline-in-acute-kidney-disease-100606966","NCT07182422","AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease","Impact of Kremezin on Renal Recovery and Uremic Toxin Levels in Patients With Acute Kidney Disease","ASTRA-AKD","Inclusion\u002FExclusion Criteria： Inclusion criteria\n\n1. Age between 18 and 80 years.\n2. Diagnosis of acute kidney disease (AKD) during hospitalization, with AKD stage 2 or 3 according to the KDIGO-AKD criteria, defined by an increase in serum creatinine to 2 times or more from baseline within 7 to 90 days.\n3. Post-discharge estimated glomerular filtration rate (eGFR) between 30 and 60 ml\u002Fmin\u002F1.73m², calculated using the MDRD equation.\n4. Hospitalization duration not exceeding 1 month.\n\nExclusion criteria\n\n1. Patients with cancer or hematological malignancies.\n2. Patients with AKD etiologies that cannot be managed in an outpatient setting (e.g., diabetic foot, obstructive uropathy with sepsis, cirrhosis).\n\n1\\. Patients presenting any of the following conditions, considered as excessively vulnerable populations or other conditions:\n\n* Bedridden.\n* Requiring nasogastric tube feeding.\n* Long-term use of oxygen therapy.\n* Use of urinary catheters.\n\nPatients unsuitable for AST-120 treatment, including:\n\n* Patients with severe constipation (defined as requiring the daily use of more than one laxative).\n* Patients with abnormal liver function (defined as ALT levels greater than 5 times the upper limit or total bilirubin \\> 2mg\u002FdL).\n* Patients with a history of peptic ulcers within the last month.\n* Pregnant women.\n* Patients allergic to the study drug.","80 Years",{"count":199,"type":21},[87],"The primary goal of this clinical trial is to evaluate the efficacy of AST-120 (Kremezin®) in combination with standard care in reducing the levels of protein-bound uremic toxins (PBUTs), specifically indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), in patients with acute kidney disease (AKD). The trial aims to assess whether AST-120 can prevent further renal deterioration and slow the progression from AKD to chronic kidney disease (CKD) by mitigating the accumulation of PBUTs. Additionally, the study will investigate the potential of AST-120 to reduce the risk of CKD-associated complications, including cardiovascular disease, by reducing PBUT levels in AKD patients.",[178,28],[252,28,253],"Acute Kidney Disease (AKD)","Progression from AKI to CKD","2025-09-17",{"date":256,"type":45},"2025-09-19",{"date":258,"type":21},"2025-09-15",{"date":260,"type":21},"2027-03-13",{"name":262,"class":52},"Chang Gung Memorial Hospital"]